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Abstract: Diabetic neuropathy is the one of the serious secondary complications of diabetes mellitus in which an 
alteration or a damage in nerve cells is observed. The nerve disorders can be developed at any time, but the possibility 
of the development increases with the longer duration of diabetes. The damage can be occurred in the sensory, motor, 
and autonomic nervous system, therefore the damage is observed in the innervated organs and systems. As a result, 
diabetic neuropathy is the most common cause of non-traumatic amputations and autonomic failure. In their lifetime, 
diabetic patients with diabetic neuropathy have a 15% incidence of undergoing one or more amputations. 
Due to the similarities of the presented pathologies to the human diseases and its the easiness, diabetes induced animal 
models are widely used in studies. Since diabetes and therefore diabetic neuropathy is a worldwide problem, it is 
necessary to examine the effects of diabetes mellitus on the neural system. The recorded compound action potentials 
revealed that diabetes is the reason of the significant increase in time to peak, rheobase and chronaxie values. 
Furthermore, the maximum depolarization, area, kinetics and the conduction velocities of both the fast and slow nerve 
fibers were found to be decreased. In addition to the decline of the conduction velocities, a shift from faster fibers to the 
slower ones was observed.  
Since the oxidant agents are unavoidable, the aim should be to minimize it as much as possible. For minimization, the 
antioxidant agents are crucial. It is also shown that beyond the inhibition of the oxidation agents, some of them also 
restore the damaged nerves.  
Currently to avoid diabetic neuropathy it is suggested to keep the glucose levels as close as possible to the normal 
values. If it is necessary pain therapy can be used to minimize the pain. The promising results of the animal studies 
show that the treatment strategies should be renewed by including the antioxidants to the daily diet to the diabetic 
patients.  
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INTRODUCTION 
A metabolic disease, which is defined by 
hyperglycemia resulting from defects in insulin 
secretion and/or insulin action named as Diabetes 
mellitus (DM). Evolution of DM ranges not only from the 
autoimmune destruction of the -cells of the pancreas 
with subsequent insulin deficiency (type I) but also from 
the abnormalities that result in a resistance to insulin 
action (type II). 
Deficient insulin action results from an inadequate 
insulin secretion and/or diminished tissue responses to 
insulin at one or more points within the complex 
pathways of hormone action. Impairment of insulin 
secretion and defects in insulin action frequently 
coexist in the same patient, and it is often unclear 
which abnormality, if either alone, is the primary cause 
of the hyperglycemia. 
The basis of the abnormalities seen in 
carbohydrate, fat, and protein metabolism in DM is 
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mainly due to deficient action of insulin on target 
tissues. The persistent hyperglycemia is associated 
with long-term tissue damages, dysfunctions, and 
failure of different organs, especially the eyes, kidneys, 
nerves, heart, and blood vessels. 
Among the others Diabetic neuropathies (DNP), the 
family of nerve disorders, are caused by DM. Since the 
damages in the nerves can be seen throughout the 
body, patients with DNP lead to numbness, pain and 
weakness in the extremities [1]. Although patients with 
DM can develop nerve problems at any time, but the 
longer they have DM, the greater the risk can be. The 
highest rate of DNP was seen among the ones who 
have had the disease for at least 25 years [2]. Indeed, 
DNP also appears to be more common among the 
patients who have had problems; (i) in controlling their 
blood glucose levels, (ii) in those with high levels of 
blood fat and blood pressure and (iii) over the age of 
40. As a result, DNP
 
is the most common cause of non-
traumatic amputations and autonomic
 
failures [3]. In 
their lifetime, diabetic patients with
 
DNP have a 15% 
incidence of undergoing one or more amputations
 
[4]. 
The formation of free radicals or oxidants is a well-
established physiological event in aerobic cells. 
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Increased oxidation within the cells convenes by 
enzymatic and nonenzymatic resources by removing 
the oxidizing species which was collectively known as 
antioxidant defense system. An imbalance between 
oxidants and antioxidants, the two terms of the 
equation defines oxidative stress (OS), and the 
consequent damages to cell molecules constitutes the 
basic tenet of several pathophysiological states, such 
as neurodegeneration, cancer, mutagenesis, 
cardiovascular diseases and aging. 
Majority of the researches dealing with the OS have 
concluded that it is the primarily cause and/or the major 
contributor to the etiology of severe pathologies with 
serious public health implications such as DM and its 
complications [5-7].  
The aim of this review is to provide up-to-date 
information on the DNP from the point of 
electrophysiology. It is also our target to summarize the 
antioxidant treatment strategies in animal models of 
DM. 
NERVE CONDUCTION STUDIES 
In principle, nerve conduction velocity (CV) 
measurements are carried out by testing how fast the 
electrical signals move through a nerve. Although the 
technique is so familiar, briefly it was performed by 
using two electrodes (stimulating and recording 
electrodes) with a known distance. Following the 
stimulation, compound action potentials (CAP) were 
recorded together with their latencies (time differences 
between the electrodes). The CV is then calculated 
simply by the dividing of distance between the 
electrodes to the latencies. Besides the easiness of the 
application the information obtained from the signal 
analysis of these records are quite valuable.  
DM INDUCED CV CHANGES 
Majority of the in vitro CV recording studies were 
carried on the experimentally induced diabetic animal 
models. Not only its easiness but also the similarities 
with its secondary pathologies, those seen in human, 
made them frequently used for the research purposes. 
The measured parameters from the in-vitro CAP 
recordings were summarized in Table 1. Four weeks of 
exposure to high blood glucose ( 400 mg/dL) resulted 
in a significant decrease in the total area, the maximum 
depolarization (MD) point of CAP recordings and an 
increase in the time required to reach the MD (TP). The 
amount of the CAP area is in relation with the number 
of actively contributing single fiber action potentials. 
Period of DM somehow results a decrease in the 
number of the active contributions of the neurons. As it 
was estimated, the excitability of neurons was 
significantly reduced during DM, which was reflected by 
a significant increase in measured rheobase and 
chronaxie values [8]. 
Latency measurements can be carried out from the 
artifact either to the start of CAP or to the MD. Former 
gives information about the speed of the fastest 
neurons while the later give information about the 
intermediately conducting neurons. Indeed, this type of 
measurements provides not only the speed but also an 
idea about the velocity contribution percentages of the 
active nerve fibers. Model studies have shown that DM 
suppressed the actively contributing nerve fibers of 
both the fast and the intermediate groups compared to 
their age matched control group values. This result 
leads us a morphological damage and/or modifications 
in ion channel activities in CV changes.  
The decision of the change whether it’s a 
morphological or a functional can be done (at least to 
certain point) by the CV distribution measurements 
mostly with the aid of collision technique [9]. In model 
studies, contributions of the nerve fibers were the 
shifted towards the relatively slower conducting side 
which then results in a decrease in the activity of the 
fastest groups. Changes in the CV due morphological 
changes with progression of DM can also be verified by 
the other model studies [10, 11]. 
OXIDATIVE STRESS AND ANTIOXIDANT SUPPLE- 
MENTATION  
In principle, both the degree of oxidative stress and 
the success of the antioxidant treatments mainly 
depend on the exposure time period and application 
protocol (time, dose and type of the antioxidant) 
respectively. Among the tested antioxidants the ones 
that have the capability of reducing the blood glucose, 
either through with insulin defects or not, seems to 
have more potent. Those are which also a power 
agents in reducing the oxidative stress markers of the 
nerve tissue.  
Lipid peroxidation measurement is an entrenched 
method to assess the extent of oxidative damage by 
free radicals. The results of many research agree that it 
was increased by hyperglycemia-induced glucose auto-
oxidation and glycation of the proteins [6, 12-16]. The 
mechanism oriented studies have shown that glucose 
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autoxidation and interaction of advanced glycation end 
products with their receptors provide the main 
contributions to the free radical generation. Indeed, 
amadori products have also produced a down-
regulation of some of the antioxidant defense enzymes 
[18]. 
Antioxidant supplementations on the other hand 
alleviate the DM induced functional defects that were 
seen in peripheral nerves via reducing the oxidative 
stress. Depending on the dose and choice of the 
antioxidant treatments many of the seen 
electrophysiological abnormalities in the nerve of 
diabetic rats has been restored nearly to its healthy 
status.  
Along with the tested antioxidants, our experiences 
have shown that selenium (Se) supplementation is the 
most powerful agent [8, 9], which has been long known 
as an essential trace element with antioxidant 
Table 1: Changes in CAP Parameters During DM and Antioxidant Treatments. In the Table: TP: Time Required to 
Reach to the Peak; MD: Maximum Depolarization Value; ± dV/dt: Up and Down Kinetics of CAP; Latency: 
Measure to AP and Peak of CAP; CVD: Conduction Velocity Distribution.  Refers to Increase,  Refers 
Decrease,  Refers Normalization to Control Values Whereas NC Means no Change 
  Tested Antioxidants 
Measured 
Parameter 
DM 
Selenium 
(7 μmol/kg/day) 
4 Weeks 
Coenzyme Q10 
(10 mg/kg/day) 
2 Weeks 
-Lipoic Acid 
(100 mg/kg/day) 
2 Weeks 
Rheobase    NC 
Chronaxie    NC 
TP   NC NC 
MD   NC NC 
+dV/dt    NC 
-dV/dt    NC 
Latency     
AP     
Peak   NC NC 
CAP Area     
CVD shift slower  higher higher 
 
 
Figure 1: Sample trace of CAP recorded from the distal end of sciatic nerve from a rat. Vertically positioned dash lines 
represents the time line periods for the corresponding parameter. Arrow shows the point of measurement. The abbreviations; 
MD: Maximum depolarization value; TP: time required to reach the MD point; Latencies used for the two CV measurements 
LAP: for the calculation of the fastest group of CVs; and LMD: for intermediate ones. 
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properties. Indeed, Se has shown an insulin mimetic 
effect in streptozotocin induced model studies [15, 16]. 
The antioxidant enzymes such as glutathione 
peroxidase (family of an enzyme with peroxidase 
activity) and thioredoxin reductase (group of enzymes 
that reduce thioredoxins) also include Se in their 
structure [17].  
Antioxidant supplementation to the diabetic animals 
blocks and/or restores the DM-induced functional 
remodelling in the nerve tissue [9, 19-25]. From the 
electrophysiological point of view, promising results for 
the clinical applications obtained by these 
supplementations are summarized in Table 1.  
CONCLUSIONS AND REMARKS 
Besides the fundamental importance of the oxygen, 
in an evolutionary manner probably the only 
disadvantage of the aerobic respiration is the oxidation. 
Since it is almost impossible to prevent the formation of 
these naturally occurring agents we have to supply 
antioxidants through our diets. In addition to their 
natural occurrence, their presence can be augmented 
and cause a stress during disease cases such as DNP.  
The animal model of DM is chosen widely for the 
research purposes not only of its easiness but also 
pathological similarities that was seen in man. The 
tested antioxidants in these animal models provide 
promising results on the DM induced both the 
functional and the structural alterations. Depending on 
the dose and the exposure time many of the DM 
induced electrophysiological changes can be 
normalized by the antioxidant treatments such as CVs 
and their distributions. 
Besides the presence of these charming effects, the 
clinical treatment strategies are frequently exclude 
antioxidant included treatments. The integration of the 
antioxidants to DM treatments in the patients is 
suggested and topic oriented further researches are 
needed. 
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